CASI Pharmeceuticals

View All
Casi Pharmaceuticals

CASI Pharmaceuticals CEO Ken K. Ren, PhD rang the closing bell at NASDAQ on Thursday, June 11, 2015 4PM.

About Us

CASI is a biopharmaceutical company focused on the acquisition, development, and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market, with a focus on China and the U.S.

Learn More

In the News

CASI's turnaround turns eastward; firm seeks to be Celgene of China

Read Article →


Phase II clinical and molecular trial of oral ENMD-2076 in clear cell ovarian cancer (CCOC): A study of the Princess Margaret Phase 2 consortium

Download →


Kinase Inhibitor Demonstrates Efficacy in a Patient-Derived Xenograft Model of Fibrolamellar Hepatocellular Carcinoma featuring DNAJB1-PRKACA Fusion

Download →

Receive press releases via email